1-11 of 11
Antje Hoering
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials

Open Access
Hillary S. Andrews, Nevine Zariffa, Katherine K. Nishimura, Stephanie H. Choi, Shibing Deng, Megan Eisele, Carin R. Espenschied, Emily M. Goren, Minakshi Guha, Samuel Hong, Dilafruz Juraeva, Nicole Krämer, Li Liu, Jean-Francois Martini, Brittany A. McKelvey, Geoffrey R. Oxnard, Gary A. Pestano, Lynne Poole, Adam Rosenthal, Anna M. Szpurka, Diana Merino Vega, Christine Ward, Sameera R. Wijayawardana, Antje Hoering, Mark D. Stewart, Jeff D. Allen
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (11): 2162–2172.
https://doi.org/10.1158/1078-0432.CCR-24-3612
Published: 03 June 2025
View article titled, ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials
Open the PDF for ctDNA Clearance as an Early Indicator of Improved Clinical Outcomes in Advanced NSCLC Treated with TKI: Findings from an Aggregate Analysis of Eight Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120

Available to Purchase
Madhav V. Dhodapkar, Rachael Sexton, Antje Hoering, Frits Van Rhee, Bart Barlogie, Robert Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (22): 5814–5819.
https://doi.org/10.1158/1078-0432.CCR-20-2119
Published: 13 November 2020
View article titled, Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120
Open the PDF for Race-Dependent Differences in Risk, Genomics, and Epstein–Barr Virus Exposure in Monoclonal Gammopathies: Results of SWOG S0120 in another window
Journal Articles

Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma

Available to Purchase
Sikander Ailawadhi, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D. Cohen, Eric M. Rohren, Stephen Heitner, Kevin Kelly, Niklas J. Mackler, David M. Baer, Antje Hoering, Brian Durie, Robert Z. Orlowski
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15): 3969–3978.
https://doi.org/10.1158/1078-0432.CCR-19-1997
Published: 03 August 2020
View article titled, Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma
Open the PDF for Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma in another window
Journal Articles

BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma

Available to Purchase
Eileen M. Boyle, Cody Ashby, Ruslana G. Tytarenko, Shayu Deshpande, Hongwei Wang, Yan Wang, Adam Rosenthal, Jeffrey Sawyer, Erming Tian, Erin Flynt, Antje Hoering, Sarah K. Johnson, Michael W. Rutherford, Christopher P. Wardell, Michael A. Bauer, Charles Dumontet, Thierry Facon, Sharmilan Thanendrarajan, Carolina D. Schinke, Maurizio Zangari, Frits van Rhee, Bart Barlogie, David Cairns, Graham Jackson, Anjan Thakurta, Faith E. Davies, Gareth J. Morgan, Brian A. Walker
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (10): 2422–2432.
https://doi.org/10.1158/1078-0432.CCR-19-1507
Published: 15 May 2020
View article titled, BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma
Open the PDF for BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma

Free
Carolina Schinke, Pingping Qu, Syed J. Mehdi, Antje Hoering, Joshua Epstein, Sarah K. Johnson, Frits van Rhee, Maurizio Zangari, Sharmilan Thanendrarajan, Bart Barlogie, Faith E. Davies, Shmuel Yaccoby, Gareth J. Morgan
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (12): 2913–2919.
https://doi.org/10.1158/1078-0432.CCR-17-2627
Published: 14 June 2018
View article titled, The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma
Open the PDF for The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants

Free
Yogesh S. Jethava, Alan Mitchell, Joshua Epstein, Maurizio Zangari, Shmuel Yaccoby, Erming Tian, Sarah Waheed, Rashid Khan, Xenofon Papanikolaou, Monica Grazziutti, Michele Cottler-Fox, Nathan Petty, Douglas Steward, Susan Panozzo, Clyde Bailey, Antje Hoering, John Crowley, Jeffrey Sawyer, Gareth Morgan, Bart Barlogie, Frits van Rhee
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2665–2672.
https://doi.org/10.1158/1078-0432.CCR-15-2620
Published: 31 May 2017
View article titled, Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants
Open the PDF for Adverse Metaphase Cytogenetics Can Be Overcome by Adding Bortezomib and Thalidomide to Fractionated Melphalan Transplants in another window
Includes: Supplementary data
Journal Articles

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma

Free
James E. McDonald, Marcus M. Kessler, Michael W. Gardner, Amy F. Buros, James A. Ntambi, Sarah Waheed, Frits van Rhee, Maurizio Zangari, Christoph J. Heuck, Nathan Petty, Carolina Schinke, Sharmilan Thanendrarajan, Alan Mitchell, Antje Hoering, Bart Barlogie, Gareth J. Morgan, Faith E. Davies
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (8): 1981–1987.
https://doi.org/10.1158/1078-0432.CCR-16-0235
Published: 13 April 2017
View article titled, Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma
Open the PDF for Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma in another window
Includes: Supplementary data
Journal Articles

Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

Free
Christoph J. Heuck, Jackie Szymonifka, Emily Hansen, John D. Shaughnessy, Jr, Saad Z. Usmani, Frits van Rhee, Elias Anaissie, Bijay Nair, Sarah Waheed, Yazan Alsayed, Nathan Petty, Clyde Bailey, Joshua Epstein, Antje Hoering, John Crowley, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5499–5506.
https://doi.org/10.1158/1078-0432.CCR-12-0019
Published: 30 September 2012
View article titled, Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1
Open the PDF for Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1 in another window
Includes: Supplementary data
Journal Articles

Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents

Free
Antje Hoering, Mike LeBlanc, John Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (4): 640–646.
https://doi.org/10.1158/1078-0432.CCR-10-1262
Published: 15 February 2011
View article titled, Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents
Open the PDF for Seamless Phase I-II Trial Design for Assessing Toxicity and Efficacy for Targeted Agents in another window
Journal Articles

Randomized Phase III Clinical Trial Designs for Targeted Agents

Free
Antje Hoering, Mike LeBlanc, John J. Crowley
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (14): 4358–4367.
https://doi.org/10.1158/1078-0432.CCR-08-0288
Published: 15 July 2008
View article titled, Randomized Phase III Clinical Trial Designs for Targeted Agents
Open the PDF for Randomized Phase III Clinical Trial Designs for Targeted Agents in another window
Journal Articles

Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling

Free
Jeffrey Haessler, John D. Shaughnessy, Jr., Fenghuang Zhan, John Crowley, Joshua Epstein, Frits van Rhee, Elias Anaissie, Mauricio Pineda-Roman, Maurizio Zangari, Klaus Hollmig, Abid Mohiuddin, Yazan Alsayed, Antje Hoering, Guido Tricot, Bart Barlogie
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (23): 7073–7079.
https://doi.org/10.1158/1078-0432.CCR-07-0527
Published: 03 December 2007
View article titled, Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling
Open the PDF for Benefit of Complete Response in Multiple Myeloma Limited to High-Risk Subgroup Identified by Gene Expression Profiling in another window
Includes: Supplementary data